logo
Plus   Neg
Share
Email

FDA Cancels Panel Review Of Intra-Cellular Therapies' Schizophrenia Drug

Intra-Cellular Therapies Inc. (ITCI) said that the U.S. Food and Drug Administration has cancelled the Psychopharmacologic Drugs Advisory Committee meeting scheduled for July 31, 2019 to discuss the New Drug Application or NDA for lumateperone for the treatment of schizophrenia.

ITCI closed Tuesday's regular trading at $8.19, down $3.79 or 31.64 percent. But, in the after-hours tare, the stock gained $0.61 or 7.45 percent.

The company said it recently provided additional information to the FDA in response to information requests relating to non-clinical studies.

The FDA cancelled the Advisory Committee meeting to allow sufficient time to review this new and any forthcoming information as they continue the NDA review. The information may result in an extension of the September 27, 2019 Prescription Drug User Fee Act target action date for the lumateperone NDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
NASA's Osiris-Rex robotic spacecraft briefly touched down on near-Earth asteroid Bennu's surface on Tuesday to collect rock and dust samples that will be brought back to Earth in 2023. Bennu is currently more than 200 million miles, or 321 million kilometres, from Earth. Osiris-Rex launched from Cape Canaveral Air Force Station in Florida in September 2016. Amazon said Wednesday that free one-hour grocery pickup is now available to prime members at all U.S. Whole Foods Market locations. Previously, the prime members could pick up Whole Foods orders only at select stores. J.C. Penney said it is near to exiting Chapter 11 ahead of the busy December 2020 holiday season. The beleaguered retailer filed a draft asset purchase agreement towards finalization of the acquisition by Brookfield Asset Management, Inc. and Simon Property Group, Inc. They are expected to buy substantially all of J.C. Penney's retail and operating assets in a combination of cash and debt.
Follow RTT